Phathom Pharmaceuticals, Inc. (PHAT) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 8 Buy, 1 Hold.
The consensus price target is $23.33 (low: $16.00, high: $28.00), representing an upside of 84.1% from the current price $12.67.
Analysts estimate Earnings Per Share (EPS) of $-5.29 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.29 vs est $-5.29 (beat +0.1%). 2025: actual $-3.03 vs est $-3.16 (beat +4%). Analyst accuracy: 98%.
PHAT Stock — 12-Month Price Forecast
$23.33
▲ +84.14% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Phathom Pharmaceuticals, Inc., the average price target is $23.33, with a high forecast of $28.00, and a low forecast of $16.00.
The average price target represents a +84.14% change from the last price of $12.67.
Highest Price Target
$28.00
Average Price Target
$23.33
Lowest Price Target
$16.00
PHAT Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Phathom Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — PHAT
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.29
vs Est –$5.29
▲ 0.1% off
2025
Actual –$3.03
vs Est –$3.16
▲ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — PHAT
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.055B
vs Est $0.050B
▲ 8.6% off
2025
Actual $0.175B
vs Est $0.175B
▲ 0.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
